Your browser is no longer supported. Please, upgrade your browser.
Settings
MYOK MyoKardia, Inc. daily Stock Chart
MYOK [NASD]
MyoKardia, Inc.
Index- P/E- EPS (ttm)-5.22 Insider Own0.40% Shs Outstand46.78M Perf Week-8.27%
Market Cap3.23B Forward P/E- EPS next Y-5.64 Insider Trans-42.66% Shs Float44.12M Perf Month-5.16%
Income-233.10M PEG- EPS next Q-1.45 Inst Own- Short Float11.85% Perf Quarter21.99%
Sales12.40M P/S260.16 EPS this Y-1.60% Inst Trans-0.09% Short Ratio13.47 Perf Half Y29.11%
Book/sh9.81 P/B7.03 EPS next Y8.30% ROA-43.10% Target Price84.73 Perf Year64.03%
Cash/sh8.92 P/C7.73 EPS next 5Y- ROE-46.20% 52W Range39.01 - 78.28 Perf YTD-5.39%
Dividend- P/FCF- EPS past 5Y-26.90% ROI-19.90% 52W High-11.91% Beta2.02
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low76.78% ATR2.63
Employees220 Current Ratio9.60 Sales Q/Q- Oper. Margin- RSI (14)44.37 Volatility3.93% 3.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-681.00% Profit Margin- Rel Volume0.61 Prev Close69.94
ShortableYes LT Debt/Eq0.00 EarningsFeb 03 AMC Payout- Avg Volume388.07K Price68.96
Recom1.60 SMA20-5.06% SMA503.12% SMA20024.04% Volume236,378 Change-1.40%
Sep-20-19Initiated Guggenheim Buy
Oct-01-18Initiated Cantor Fitzgerald Overweight $90
Sep-28-18Initiated Citigroup Buy $90
Sep-10-18Initiated Morgan Stanley Overweight $72
Jul-10-18Initiated BofA/Merrill Buy $71
Jan-18-18Resumed Credit Suisse Outperform $60
Dec-12-17Initiated JP Morgan Overweight $54
Sep-19-17Reiterated Credit Suisse Outperform $45 → $55
Dec-04-15Initiated Wells Fargo Outperform
Nov-23-15Initiated Wedbush Outperform $22
Nov-23-15Initiated Credit Suisse Outperform $18
Jan-06-20 08:00AM  MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-19 09:17AM  Biotech Stocks Are In a Position to Break Out in 2020, Analysts Say Barrons.com
Dec-09-19 02:19PM  MyoKardia's (NASDAQ:MYOK) Wonderful 377% Share Price Increase Shows How Capitalism Can Build Wealth Simply Wall St.
Dec-06-19 11:11PM  Hedge Funds Love MyoKardia, Inc. (MYOK) Way More Than These 3 Stocks Insider Monkey
Dec-02-19 02:00PM  Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-27-19 08:00AM  MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference GlobeNewswire
Nov-11-19 07:30AM  MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten GlobeNewswire -7.60%
07:30AM  MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten GlobeNewswire
Nov-06-19 04:05PM  MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference GlobeNewswire
Nov-04-19 04:44PM  MyoKardia Reports Third Quarter 2019 Financial Results GlobeNewswire
08:30AM  MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019 GlobeNewswire
Oct-28-19 08:30AM  MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population GlobeNewswire
Oct-08-19 10:57AM  Here's Why We're Not Too Worried About MyoKardia's (NASDAQ:MYOK) Cash Burn Situation Simply Wall St.
Sep-26-19 04:05PM  MyoKardia to Present at 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-10-19 08:44AM  MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients GlobeNewswire
Aug-31-19 05:00AM  MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019 GlobeNewswire
Aug-28-19 04:05PM  MyoKardia to Participate in September Investor Conferences GlobeNewswire
04:00PM  Biotech Stock On The Radar: MyoKardia Bets On Precision Medicine For Heart Health Benzinga
Aug-26-19 08:30AM  MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019 GlobeNewswire
Aug-23-19 09:45AM  Have Insiders Been Selling MyoKardia, Inc. (NASDAQ:MYOK) Shares This Year? Simply Wall St.
Aug-22-19 12:01PM  MyoKardia Begins Dosing in Phase I Study on Heart Candidate Zacks
Aug-21-19 08:30AM  MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy GlobeNewswire
Aug-15-19 08:30AM  MyoKardia Launches 2nd Annual MyoSeeds Research Grants Program to Advance Independent Research in Heart Disease GlobeNewswire
Aug-14-19 10:54AM  Edited Transcript of MYOK earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 01:40PM  MyoKardia, Inc. (MYOK) Q2 2019 Earnings Call Transcript Motley Fool +6.74%
Aug-07-19 08:15PM  MyoKardia (MYOK) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:05PM  MyoKardia Reports Second Quarter 2019 Financial Results GlobeNewswire
08:00AM  MyoKardia to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-31-19 04:05PM  MyoKardia to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019 GlobeNewswire
Jul-18-19 08:30AM  MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi GlobeNewswire +7.49%
Jun-24-19 08:30AM  MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy GlobeNewswire
Jun-14-19 08:28AM  Were Hedge Funds Right About Flocking Into MyoKardia, Inc. (MYOK) ? Insider Monkey
Jun-12-19 11:25AM  The MyoKardia (NASDAQ:MYOK) Share Price Is Up 218% And Shareholders Are Boasting About It Simply Wall St.
May-28-19 08:30AM  MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece GlobeNewswire
May-14-19 05:03PM  Edited Transcript of MYOK earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-10-19 12:34AM  MyoKardia, Inc. (MYOK) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 07:35PM  MyoKardia (MYOK) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:31PM  MyoKardia: 1Q Earnings Snapshot Associated Press
07:46AM  These 3 revolutionary genomics companies are changing lives for patients and investors MarketWatch
May-08-19 04:10PM  MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
May-07-19 04:10PM  MyoKardia Announces Inaugural MyoSeeds Research Grants Program Awardees GlobeNewswire
May-02-19 08:00AM  MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019 GlobeNewswire
Apr-30-19 02:52PM  Heres What Hedge Funds Think About MyoKardia, Inc. (MYOK) Insider Monkey -5.10%
08:30AM  Clinical Trial Results from MyoKardias Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine GlobeNewswire
Apr-12-19 09:10AM  Can We See Significant Institutional Ownership On The MyoKardia, Inc. (NASDAQ:MYOK) Share Register? Simply Wall St.
Mar-27-19 07:30AM  Detailed Research: Economic Perspectives on TIER REIT, MyoKardia, Radian Group, Packaging Corporation of America, Air Products and Chemicals, and ProAssurance What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-26-19 06:45PM  MyoKardia Announces Pricing of Public Offering of Common Stock GlobeNewswire
07:36AM  The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs Benzinga
Mar-25-19 04:01PM  MyoKardia Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-06-19 08:00AM  MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference GlobeNewswire
Mar-05-19 10:02PM  Edited Transcript of MYOK earnings conference call or presentation 4-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
08:48AM  MyoKardia (MYOK) in Focus: Stock Moves 7.3% Higher Zacks
Mar-04-19 09:42AM  MyoKardia stock up 6% after safety-and-efficacy study of HCM treatment shows reduction in symptoms MarketWatch +7.27%
08:02AM  MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM GlobeNewswire
Feb-28-19 09:28AM  Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million American City Business Journals
08:30AM  MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-26-19 05:28PM  Big Pharma trims projects and a potential $1 billion in payments from collaboration with small Peninsula biotech American City Business Journals
Feb-21-19 04:00PM  3 Top Healthcare Stocks to Buy in February Motley Fool
Feb-11-19 10:42AM  Zacks.com featured highlights include: Athene, MyoKardia and Euronav Zacks
Feb-08-19 08:55AM  3 Earnings Acceleration Stocks You Really Need to Look At Zacks
Feb-04-19 01:58PM  MyoKardia, Inc. (NASDAQ:MYOK) Insiders Have Been Selling Simply Wall St.
08:15AM  Market Trends Toward New Normal in Duke Energy, VICI Properties, MyoKardia, FLIR, TIER REIT, and ChannelAdvisor Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-23-19 08:30AM  MyoKardia Appoints William Fairey as Chief Commercial Officer GlobeNewswire
Jan-13-19 11:14AM  Weekly CEO Buys Highlight GuruFocus.com
Jan-09-19 04:05PM  Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019 TheStreet.com
Jan-03-19 08:00AM  MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-19 04:35PM  Why Tesla, MyoKardia, and Hologic Slumped Today Motley Fool -14.14%
08:00AM  MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi GlobeNewswire
Dec-14-18 01:42AM  Hedge Funds Are Buying MyoKardia, Inc. (MYOK) Insider Monkey
Dec-11-18 08:30AM  MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients GlobeNewswire
Dec-05-18 04:01PM  MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-04-18 08:38AM  Is MyoKardia Inc (NASDAQ:MYOK) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Nov-28-18 08:55AM  Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy Fundamental Analysis, Key Performance Indications GlobeNewswire +6.18%
Nov-12-18 07:30AM  MyoKardia Presents Preclinical Evidence of Mavacamtens Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions GlobeNewswire
Nov-08-18 05:34PM  Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion for a higher price American City Business Journals +6.99%
Nov-07-18 08:50PM  MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:48PM  MyoKardia: 3Q Earnings Snapshot Associated Press
04:38PM  All this 500,000-square-foot Berkeley biotech project needs is a developer American City Business Journals
04:30PM  MyoKardia Reports Third Quarter 2018 Financial Results GlobeNewswire
08:01AM  MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Nov-05-18 08:00AM  MyoKardia to Present Clinical Evidence of Mavacamtens Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions GlobeNewswire
08:00AM  MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions GlobeNewswire
Nov-01-18 10:23AM  Big pharma leases almost 500,000 square feet for new research center American City Business Journals
Oct-31-18 10:10AM  Bears Are Doing an EKG Test on MyoKardia TheStreet.com
Oct-30-18 07:30AM  MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day GlobeNewswire
Oct-29-18 10:17AM  Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more American City Business Journals -5.69%
Oct-25-18 10:34AM  MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up? Zacks +6.00%
12:00AM  MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe GlobeNewswire
Oct-24-18 04:30PM  MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy GlobeNewswire -6.60%
Oct-22-18 08:30AM  MyoKardia to Host R&D Day on October 30, 2018 GlobeNewswire
Oct-19-18 08:30AM  Recent Analysis Shows Vipshop, MyoKardia, HudBay Minerals, Nordic American Tankers, Yum China, and TIM Participacoes S.A. Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Sep-24-18 11:10AM  Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms American City Business Journals
08:01AM  MyoKardia to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-10-18 04:10PM  A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others Benzinga
Aug-29-18 04:01PM  MyoKardia to Present at Two Upcoming Investor Conferences in September GlobeNewswire
Aug-21-18 07:30AM  Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-08-18 08:05PM  MyoKardia (MYOK) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:02PM  MyoKardia: 2Q Earnings Snapshot Associated Press
04:02PM  MyoKardia Reports Second Quarter 2018 Financial Results GlobeNewswire
03:10PM  Backed with $140M, startup launches three-pronged attack on liver diseases American City Business Journals
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GIANAKAKOS ANASTASIOSPresident and CEOJan 14Sale75.395,000376,96591,777Jan 14 08:26 PM
McDowell Robert ScottChief Scientific OfficerJan 06Sale68.452,650181,3955,383Jan 07 07:39 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 06Sale68.4512,687868,43996,777Jan 07 07:39 PM
Harris Taylor C.Chief Financial OfficerJan 06Sale68.451,683115,2034,993Jan 07 07:39 PM
LADD CYNTHIA JGeneral CounselJan 06Sale68.451,849126,5662,851Jan 07 07:36 PM
Bauer JakeChief Business OfficerJan 06Sale68.452,466168,80057,491Jan 07 05:15 PM
Bauer JakeChief Business OfficerJan 03Option Exercise1.5110,00015,10059,957Jan 07 05:15 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 03Sale71.805,000359,008109,464Jan 03 08:18 PM
Bauer JakeChief Business OfficerDec 20Option Exercise11.1517,500195,05062,498Dec 23 09:07 PM
Bauer JakeChief Business OfficerDec 20Sale70.0718,9161,325,42143,582Dec 23 09:07 PM
GIANAKAKOS ANASTASIOSPresident and CEODec 02Sale65.025,000325,09886,514Dec 04 04:26 PM
Bauer JakeChief Business OfficerNov 29Sale65.608,136533,71144,998Dec 02 04:10 PM
Bauer JakeChief Business OfficerNov 27Sale65.1313,096852,97753,134Dec 02 04:10 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 04Sale59.075,000295,36591,514Nov 06 06:33 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 03Sale55.001,00055,00096,470Oct 04 05:27 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 02Sale52.284,000209,11197,470Oct 04 05:27 PM
Lee JuneEVP, Chief Development OfficerSep 23Option Exercise11.9512,625150,86917,204Sep 24 06:23 PM
Lee JuneEVP, Chief Development OfficerSep 23Sale59.5113,051776,7244,153Sep 24 06:23 PM
Bauer JakeChief Business OfficerSep 20Option Exercise10.6419,700209,62585,768Sep 24 04:05 PM
Bauer JakeChief Business OfficerSep 20Sale60.0919,7001,183,77766,068Sep 24 04:05 PM
Lee JuneEVP, Chief Development OfficerSep 19Option Exercise11.955,43564,94810,014Sep 20 05:31 PM
Lee JuneEVP, Chief Development OfficerSep 19Sale57.085,435310,2544,579Sep 20 05:31 PM
GIANAKAKOS ANASTASIOSPresident and CEOSep 11Sale55.001,00055,000101,470Sep 12 04:16 PM
GIANAKAKOS ANASTASIOSPresident and CEOSep 03Sale52.154,000208,585102,470Sep 05 04:05 PM
Lee JuneEVP, Chief Development OfficerAug 09Option Exercise11.954,56554,5529,144Aug 12 08:40 PM
Lee JuneEVP, Chief Development OfficerAug 09Sale57.004,565260,2194,579Aug 12 08:40 PM
GIANAKAKOS ANASTASIOSPresident and CEOAug 08Sale55.091,00055,090106,470Aug 09 05:11 PM
GIANAKAKOS ANASTASIOSPresident and CEOAug 02Sale53.234,000212,935107,470Aug 05 04:05 PM
GIANAKAKOS ANASTASIOSPresident and CEOJul 22Sale55.001,00055,000111,470Jul 23 04:05 PM
GIANAKAKOS ANASTASIOSPresident and CEOJul 05Sale49.734,000198,903112,470Jul 08 05:35 PM
Harris Taylor C.Chief Financial OfficerApr 05Sale53.301,32470,5692,426Apr 09 06:19 PM
Lee JuneSee RemarksMar 14Option Exercise11.951,75821,0084,178Mar 18 05:32 PM
Lee JuneEVP, Chief Development OfficerFeb 25Option Exercise11.953,00035,85022,157Oct 29 08:31 PM
Sanofi10% OwnerFeb 13Sale37.664,168,899157,000,7360Feb 15 06:05 AM